Aquestive Therapeutics, Inc. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
Aquestive Therapeutics, Inc. (AQST) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 0 shares for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-04.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2024-11-04
- Aquestive Therapeutics, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2024-09-30 was 0.00 shares.
- Aquestive Therapeutics, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2024-06-30 was 0.00 shares.
- Aquestive Therapeutics, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2024-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- Aquestive Therapeutics, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2023-09-30 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month |
|---|---|---|---|
| 2024-09-30 | 0.00 shares 10-Q · filed 2024-11-04 | 0.00 shares 10-Q · filed 2024-11-04 | |
| 2024-06-30 | 0.00 shares 10-Q · filed 2024-08-06 | 0.00 shares 10-Q · filed 2024-08-06 | |
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-07 | ||
| 2023-09-30 | 0.00 shares 10-Q · filed 2024-11-04 | 1.55M shares 10-Q · filed 2024-11-04 | |
| 2023-06-30 | 0.00 shares 10-Q · filed 2024-08-06 | 1.91M shares 10-Q · filed 2024-08-06 | |
| 2023-03-31 | 10.56M shares 10-Q · filed 2024-05-07 | ||
| 2022-09-30 | 0.00 shares 10-Q · filed 2023-11-06 | 0.00 shares 10-Q · filed 2023-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |